MX368459B - Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. - Google Patents

Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Info

Publication number
MX368459B
MX368459B MX2016000153A MX2016000153A MX368459B MX 368459 B MX368459 B MX 368459B MX 2016000153 A MX2016000153 A MX 2016000153A MX 2016000153 A MX2016000153 A MX 2016000153A MX 368459 B MX368459 B MX 368459B
Authority
MX
Mexico
Prior art keywords
preventing
nervous system
central nervous
degenerative disorders
novel compositions
Prior art date
Application number
MX2016000153A
Other languages
English (en)
Inventor
Boyd Robert
Lee Gary
Rybczynski Philip
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX368459B publication Critical patent/MX368459B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a nuevos compuestos, así como también composiciones y métodos que los usan para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. En particular, la presente invención proporciona métodos para prevenir y/o tratar la enfermedad de Parkinson.
MX2016000153A 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central. MX368459B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25280309P 2009-10-19 2009-10-19

Publications (1)

Publication Number Publication Date
MX368459B true MX368459B (es) 2019-10-03

Family

ID=43879775

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012004548A MX340807B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2016000153A MX368459B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012004548A MX340807B (es) 2009-10-19 2010-10-05 Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.

Country Status (26)

Country Link
US (4) US8604206B2 (es)
EP (2) EP2490532B1 (es)
JP (2) JP5805649B2 (es)
KR (3) KR101813988B1 (es)
CN (2) CN105367485B (es)
AR (1) AR078606A1 (es)
AU (3) AU2010308396B2 (es)
BR (1) BR112012009121A2 (es)
CA (1) CA2778348C (es)
CY (1) CY1118966T1 (es)
DK (1) DK2490532T3 (es)
ES (2) ES2814178T3 (es)
HR (1) HRP20170236T1 (es)
HU (1) HUE033116T2 (es)
IL (1) IL219160B (es)
LT (1) LT2490532T (es)
MX (2) MX340807B (es)
PL (1) PL2490532T3 (es)
PT (1) PT2490532T (es)
RS (1) RS55679B1 (es)
RU (2) RU2015147509A (es)
SG (1) SG10201507159XA (es)
SI (1) SI2490532T1 (es)
SM (2) SMT201700105T1 (es)
TW (1) TWI642434B (es)
WO (1) WO2011049736A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2995306T (pt) 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
DK2490532T3 (en) 2009-10-19 2017-02-27 Amicus Therapeutics Inc Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
EP2591823A1 (en) * 2011-11-11 2013-05-15 Biologische Heilmittel Heel GmbH Composition for treating or preventing neurodegenerative disorders
CA2868459A1 (en) 2012-03-27 2013-10-03 Amicus Therapeutics, Inc. Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
EP3087056A4 (en) * 2013-12-23 2017-07-19 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
US10179128B2 (en) 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
WO2018200618A1 (en) 2017-04-25 2018-11-01 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
RU2676956C1 (ru) * 2017-08-25 2019-01-11 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Антитела для связывания имиглюцеразы и их применение в аффинной хроматографии
KR101991276B1 (ko) 2018-01-19 2019-06-21 전남대학교산학협력단 신규 균주 페니실리움 아쿠아티쿰 및 이를 이용한 퇴행성 뇌질환 치료제
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3962492A4 (en) * 2019-04-29 2023-05-31 Thomas Jefferson University METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
US20240262832A1 (en) * 2021-04-30 2024-08-08 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2022232360A1 (en) * 2021-04-30 2022-11-03 Vanqua Bio, Inc. Small molecule modulators of glucocerebrosidase activity and uses thereof
WO2024163532A1 (en) * 2023-01-31 2024-08-08 Bioeutectics Corporation Use of additives (adjuvants, anti freezing agents, antimicrobial and antioxidants) in natural deep eutectic solvents and mixtures

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
AU1890295A (en) * 1994-03-09 1995-09-25 Novo Nordisk A/S Piperidines and pyrrolidines
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
JP2006507359A (ja) * 2002-10-28 2006-03-02 ノボ・ノルデイスク・エー／エス 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用
US20040082641A1 (en) * 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20070270350A1 (en) * 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
ES2364586T3 (es) * 2006-05-24 2011-09-07 Amicus Therapeutics, Inc. Sal tartrato de isofagomina y métodos de uso.
US7501439B2 (en) * 2006-05-24 2009-03-10 Amicus Therapeutics, Inc. Tartrate salt of isofagomine and methods of use
ATE555788T1 (de) * 2006-06-23 2012-05-15 Amicus Therapeutics Inc Verfahren zur behandlung neurologischer erkrankungen mittels verstärkung der beta - glucocerebrosidaseaktivität
WO2008134628A2 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
BRPI1010517A2 (pt) 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
CA2758187C (en) * 2009-04-09 2017-03-07 Robert Boyd Methods for preventing and/or treating degenerative disorders of the central nervous system
PT2995306T (pt) 2009-10-19 2019-03-29 Amicus Therapeutics Inc Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal
DK2490532T3 (en) * 2009-10-19 2017-02-27 Amicus Therapeutics Inc Hitherto UNKNOWN COMPOSITIONS FOR PREVENTION AND / OR TREATMENT OF DEGENERATIVE DISORDERS IN THE CENTRAL Nervous System
JP6061677B2 (ja) * 2009-10-19 2017-01-18 アミカス セラピューティックス インコーポレイテッド 薬理シャペロンを用いてガングリオシドの活性を増大させて、アルツハイマー病を治療するための方法
KR102023720B1 (ko) 2012-09-03 2019-09-20 엘지이노텍 주식회사 보이스 코일 모터

Also Published As

Publication number Publication date
AU2016203817A1 (en) 2016-06-30
WO2011049736A1 (en) 2011-04-28
PT2490532T (pt) 2017-02-23
US20140080871A1 (en) 2014-03-20
EP2490532B1 (en) 2016-11-23
PL2490532T3 (pl) 2017-05-31
KR101769396B1 (ko) 2017-08-18
CN105367485B (zh) 2018-04-17
KR20170096220A (ko) 2017-08-23
US10421724B2 (en) 2019-09-24
JP6258245B2 (ja) 2018-01-10
EP2490532A4 (en) 2013-06-12
BR112012009121A2 (pt) 2017-08-29
US20160326114A1 (en) 2016-11-10
SMT201700105B (it) 2017-03-08
TWI642434B (zh) 2018-12-01
CA2778348A1 (en) 2011-04-28
AU2017272296B2 (en) 2019-07-11
EP2490532A1 (en) 2012-08-29
RS55679B1 (sr) 2017-07-31
US20110092541A1 (en) 2011-04-21
ES2814178T3 (es) 2021-03-26
US9409862B2 (en) 2016-08-09
KR101880411B1 (ko) 2018-07-19
SG10201507159XA (en) 2015-10-29
AU2016203817B2 (en) 2017-09-07
SMT201700105T1 (it) 2017-03-08
CN105367485A (zh) 2016-03-02
JP2015157822A (ja) 2015-09-03
HK1219724A1 (zh) 2017-04-13
HUE033116T2 (en) 2017-11-28
JP2013508366A (ja) 2013-03-07
MX340807B (es) 2016-07-27
US8604206B2 (en) 2013-12-10
IL219160B (en) 2018-12-31
JP5805649B2 (ja) 2015-11-04
CY1118966T1 (el) 2018-01-10
KR101813988B1 (ko) 2018-01-02
SI2490532T1 (sl) 2017-03-31
TW201116279A (en) 2011-05-16
AU2010308396B2 (en) 2016-04-28
AU2017272296A1 (en) 2018-01-25
RU2581058C2 (ru) 2016-04-10
EP3143875A1 (en) 2017-03-22
RU2015147509A (ru) 2019-01-14
LT2490532T (lt) 2017-03-27
MX2012004548A (es) 2012-07-04
CA2778348C (en) 2022-08-23
DK2490532T3 (en) 2017-02-27
KR20120104549A (ko) 2012-09-21
ES2617192T3 (es) 2017-06-15
IL219160A0 (en) 2012-06-28
US20180273474A1 (en) 2018-09-27
EP3143875B1 (en) 2020-05-27
KR20180001588A (ko) 2018-01-04
AU2010308396A1 (en) 2012-05-03
HRP20170236T1 (hr) 2017-04-07
CN102655747A (zh) 2012-09-05
AR078606A1 (es) 2011-11-23
RU2012120759A (ru) 2013-11-27

Similar Documents

Publication Publication Date Title
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
SG179120A1 (en) Novel compounds
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY161415A (en) A homeopathic formulation
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2010007392A (es) Antagonistas de trpa1.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010007391A (es) Antagonistas de trpa1.
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2010010877A (es) Compuestos y composiciones como inhibidores de itpkb.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
TW200642690A (en) Composition for treating central nervous system disorders